ACRO Biomedical Gets Taiwan MOHW Nod for ABCcolla® Collagen Eye Matrix

ACRO Biomedical Co.,  announced that its ABCcolla® Collagen Ophthalmic Matrix has received regulatory approval from Taiwan's&n...

April 14, 2025 | Monday | News
Amgen’s IMDELLTRA® Shows Survival Benefit in Phase 3 Trial for Small Cell Lung Cancer

Amgen, announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with ...

April 14, 2025 | Monday | News
Vantage Biosciences Doses First Patient in Phase 2 Trial of VX-01 for Diabetic Retinopathy

Vantage Biosciences is a clinical-stage biotechnology company developing innovative therapies for the treatment of diabetic eye diseases. The company ...

April 14, 2025 | Monday | News
FDA Clears argenx SE’s VYVGART Hytrulo Prefilled Syringe for Patient Self-Injection

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that the U.S. Food a...

April 11, 2025 | Friday | News
Lunit and National Cancer Institute Partner to Advance AI-Driven Cancer Research

 Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced a collaboration with the National Cancer Institu...

April 11, 2025 | Friday | News
Cellistic Introduces Echo™-NK Platform to Power Scalable Off-the-Shelf NK Cell Therapies for Cancer and Autoimmune Diseases

Cellistic, a pioneer in induced pluripotent stem cells (iPSC)-based cell therapies, is launching the Echo™-NK platform to enable the scalable manuf...

April 11, 2025 | Friday | News
Seegene Unveils Vision for Next-Gen PCR Automation with CURECA™ System

Seegene Inc., a global leader in molecular diagnostics (MDx), is advancing its vision for innovation in laboratory automation with the development of ...

April 10, 2025 | Thursday | News
AbbVie’s RINVOQ® Becomes First Oral JAK Inhibitor Approved in EU for Giant Cell Arteritis

AbbVie announced that the European Commission (EC) granted marketing authorization to RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment ...

April 10, 2025 | Thursday | News
FDA Approves Opdivo® Plus Yervoy® as First-Line Treatment for MSI-H/dMMR Metastatic Colorectal Cancer

 Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) plus Yervoy®...

April 10, 2025 | Thursday | News
Assembly Biosciences Showcases Promising HSV Treatment Data at ESCMID 2025

Assembly Biosciences, Inc., a biotechnology company developing innovative therapeutics targeting serious viral diseases,  announced data from its herp...

April 10, 2025 | Thursday | News
Science 37 Achieves Second Successful FDA Inspection, Reaffirming Commitment to High-Quality Clinical Trials

Science 37, a leader in enhancing patient access to clinical trials, announced the successful completion of its second FDA inspection, reaffirming the qual...

April 10, 2025 | Thursday | News
China’s Telitacicept Sets New Benchmark in gMG Treatment with Landmark Phase 3 Results

Impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰爱®...

April 09, 2025 | Wednesday | News
CareMed Joins Limited Distribution Network for Vanrafia™ (Atrasentan) in Treatment of Primary IgAN

CareMed, an independent specialty pharmacy, is in the Limited Distribution Network for Vanrafia™ (atrasentan), for the reduction of proteinuria ...

April 08, 2025 | Tuesday | News
Halozyme’s ENHANZE® Technology Powers European Approval of Subcutaneous RYBREVANT® for Advanced NSCLC Treatment

 Halozyme Therapeutics, Inc.announced that Janssen-Cilag International NV, a Johnson & Johnson company, has received European Commission (EC) mark...

April 08, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close